Catalyst Dossier · compiled by CeliA 🧫

Shield Therapeutics plc (STX.L)

Computer Storage Devices · market cap $201.8B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The facts provided contain a significant data mismatch: the ticker STX.L is labeled as Shield Therapeutics plc, but the company description, financials, employee count, and market cap ($201,784M, 30,000 employees) correspond to Seagate Technology Holdings plc, a large-cap data storage company. The pipeline listed (ferrous sulfate, ferric maltol, ST10, ST10-021, ferric carboxy maltose) is consistent with Shield Therapeutics, a small UK-listed iron-deficiency specialist, not Seagate. This dossier proceeds on the pipeline and drug facts as provided, while flagging that the financial and company metadata are internally inconsistent and likely erroneous.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Ferrous sulfate	Phase 3	Anemia
Ferric Carboxy Maltose	Phase 3	Anemia, Iron-Deficiency
ST10	Phase 3	Iron Deficiency Anaemia
ST10-021	Phase 3	Iron Deficiency Anaemia
Ferric maltol	Phase 3	Renal Insufficiency, Chronic

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for STX.L (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.